--- title: "CSPC Pharmaceutical's self-developed INHBE small nucleic acid drug approved for overweight/obesity clinical trial" type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/39081125.md" description: "China Medical System Holdings Limited (“CMS”) is pleased to announce that its self-developed innovative drug, the INHBE small nucleic acid drug CMS-D008 injection (“CMS-D008”), received the drug clinical trial approval notice issued by the China National Medical Products Administration (“NMPA”) on March 4, 2026. NMPA has agreed to conduct clinical trials of CMS-D008 injection for overweight or obesity. About CMS-D008CMS-D008 is a subcutaneously injected siRNA drug..." datetime: "2026-03-05T11:12:55.000Z" locales: - [en](https://longbridge.com/en/topics/39081125.md) - [zh-CN](https://longbridge.com/zh-CN/topics/39081125.md) - [zh-HK](https://longbridge.com/zh-HK/topics/39081125.md) author: "[亚太商讯那些事儿](https://longbridge.com/en/profiles/18018177.md)" --- # CSPC Pharmaceutical's self-developed INHBE small nucleic acid drug approved for overweight/obesity clinical trial China Medical System Holdings Limited ("CMS") is pleased to announce that its self-developed innovative drug, the INHBE small nucleic acid drug CMS-D008 injection ("CMS-D008"), received a drug clinical trial approval notice issued by the China National Medical Products Administration ("NMPA") on March 4, 2026. The NMPA has agreed to conduct clinical trials of the CMS-D008 injection for overweight or obesity. **About CMS-D008** CMS-D008 is a subcutaneously injected siRNA drug that targets and inhibits the expression of the inhibin subunit beta E (INHBE) gene in the liver, downregulating the level of the INHBE-encoded protein Activin E, thereby reducing the activation of the fat metabolism pathway Activin E-ALK7 and effectively decreasing lipid accumulation. Preclinical studies suggest that CMS-D008 efficiently and continuously inhibits INHBE expression. In obese animal models, it achieved significant weight loss and fat reduction effects without affecting muscle mass, with a good safety profile; it demonstrates the promising prospect of long-term, high-quality weight loss by reducing fat while preserving muscle. In the future, it may be developed to treat overweight/obesity, abdominal obesity, and related metabolic diseases. _**Reducing Fat Without Losing Muscle: A Potential Superior Treatment for Overweight/Obesity**_ Overweight or obesity is a chronic, progressive, and recurrent disease characterized by excessive accumulation or abnormal distribution and dysfunction of adipose tissue \[1\]. According to the "World Obesity Report 2025", it is predicted that by 2030, the proportion of overweight and obese adults worldwide will rise to 50%, with nearly 3 billion adults affected by a high body mass index (BMI). The number of overweight/obese adults in China is expected to reach 515 million \[2\]. Existing GLP-1RA drugs have shown good weight loss effects, primarily by acting on the central nervous system to suppress appetite and delay gastric emptying to reduce weight \[3\]. In contrast, INHBE, with a mechanism different from GLP-1 drugs, was identified through genome-wide association analysis screening. Populations with loss of INHBE function have favorable body fat distribution and beneficial metabolic characteristics \[4\]. Targeted inhibition of INHBE can precisely reduce visceral fat at the genetic level, improve metabolic status, and be more conducive to long-term weight management. **CMS-D008 Joins Forces with CMS-D005: Combining High-Efficacy Weight Loss with Long-Term Maintenance to Build a More Comprehensive Weight Management Solution** CMS-D008 will synergize with the self-developed innovative drug CMS-D005, which is currently in the clinical development stage. CMS-D008 reduces fat while preserving muscle through precise inhibition of INHBE gene expression; while CMS-D005, as a GLP-1R/GCGR dual agonist, can effectively reduce liver fat during weight loss. The synergy of the two aims to achieve efficient weight loss benefits and long-term outcome maintenance, jointly enhancing CMS's R&D capabilities and product competitiveness in the obesity/metabolic treatment field. Leveraging its established network resources in the cardiovascular metabolic disease area, CMS will accelerate the drug's R&D and commercialization process, providing patients with more comprehensive and innovative treatment options. CMS is actively preparing to conduct the relevant clinical trials, striving for the product's market launch as soon as possible. **About China Medical System Holdings Limited** China Medical System Holdings Limited is an open platform enterprise that connects pharmaceutical innovation with commercialization, managing the entire product lifecycle. It is committed to providing competitive products and services to meet unmet medical needs. CMS focuses on first-in-class (FIC) and best-in-class (BIC) innovative products, efficiently advancing the clinical research, development, and commercialization of innovative products, empowering the continuous translation of scientific research into clinical practice to benefit patients. CMS concentrates on specialty fields, possessing proven commercialization capabilities, extensive channel coverage, and expert resources across multiple disease areas. Its core marketed products have achieved leading academic and market positions. CMS continues to deepen its development around its advantageous specialty fields to consolidate competitiveness in cardio-renal metabolism/digestive/ophthalmology/skin health businesses, bringing about scale efficiency in specialties. Among them, the skin health business (DermaMed Pharmaceutical) has become a leading enterprise in its segment and is planning for an independent listing on the Stock Exchange. Simultaneously, CMS continuously promotes the operation and development of the entire R&D, production, and sales industrial chain in Southeast Asia and the Middle East to capture incremental growth in emerging markets, helping the Group achieve high-quality and sustainable development. **References/Materials** 1.Chinese Society of Endocrinology. Guidelines for Long-Term Weight Management and Clinical Application of Drugs in Obese Patients (2024 Edition). Chinese Journal of Endocrinology and Metabolism, 2024,40(7):545-564. 2.World Obesity Federation. "World Obesity Report 2025" \[EB/OL\]. London: World Obesity Federation 3.Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z 4.Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7. **CMS Disclaimer and Forward-Looking Statements** This news is not intended to promote any product to you and is not for advertising purposes. This news does not recommend any drug, medical device, and/or indication. If you wish to understand specific disease diagnosis and treatment information, please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient's specific circumstances and in accordance with the drug instructions. This news prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities and does not form the basis of or be relied upon for any contract or any other binding commitment. This news is prepared by CMS based on information and data it deems reliable, but CMS makes no statement, warranty, express or implied, or other representation, and the truthfulness, accuracy, completeness, fairness, and reasonableness of the content of this news should not be relied upon. Certain matters discussed in this news may contain statements concerning the market opportunities and business prospects of CMS, which are referred to individually or collectively as forward-looking statements. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and assumptions that are difficult to predict. CMS does not adopt any forward-looking statements and forecasts made by third parties contained in this news, and CMS assumes no responsibility for such third-party statements and forecasts. ### Related Stocks - [CMS.US](https://longbridge.com/en/quote/CMS.US.md) - [00867.HK](https://longbridge.com/en/quote/00867.HK.md) - [CMS-C.US](https://longbridge.com/en/quote/CMS-C.US.md) - [8A8.SG](https://longbridge.com/en/quote/8A8.SG.md)